H.I.G. BioVentures

H.I.G. BioVentures is the life-science investment affiliate of H.I.G. Capital, specializing in healthcare companies developing therapeutic drugs, medical devices, and diagnostics. With approximately $400 million in committed capital, the firm invests between $5 million and $40 million per company over the life of an investment. Their portfolio includes companies across various stages and sectors within the healthcare industry.

The firm's investment strategy targets companies with well-defined products and viable business models, including clinical/regulatory, reimbursement, and go-to-market strategies. H.I.G. BioVentures has a history of supporting companies like NeuWave Medical, which developed the Certus 140 thermal ablation system, and BioVectra, a contract development and manufacturing organization for active pharmaceutical ingredients.

H.I.G. BioVentures is led by Managing Directors Aaron Davidson, Bruce Robertson, and Michael Wasserman, who bring extensive experience in the life sciences sector. The firm is headquartered in Miami, Florida, and operates with a team dedicated to advancing healthcare innovations through strategic investments.